Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

2.6K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.6K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Natural History of Morquio A Syndrome.

Journal of inherited metabolic disease·2026
Same author

AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase.

International journal of molecular sciences·2026
Same author

Collagen Type II-Targeting Lentiviral Gene Therapy for Mucopolysaccharidosis IVA.

Current issues in molecular biology·2026
Same author

Long-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA.

Current issues in molecular biology·2025
Same author

Recent advances in mucopolysaccharidosis IVA treatment.

Orphanet journal of rare diseases·2025
Same author

Three-dimensional human mucopolysaccharidosis IVA chondrocyte culture reveals significant impairments in the lysosomal-mitochondrial crosstalk.

Scientific reports·2025

Related Experiment Video

Updated: Jun 17, 2025

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
11:20

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

7.6K

Potential Targeting Mechanisms for Bone-Directed Therapies.

Betul Celik1,2, Andrés Felipe Leal2,3, Shunji Tomatsu2,4,5

  • 1Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.

International Journal of Molecular Sciences
|August 10, 2024
PubMed
Summary

Targeted drug delivery for bone development faces challenges due to avascularity. Novel strategies are needed to improve specificity, reduce immunogenicity, and enhance circulation for effective skeletal treatment.

Keywords:
bone and cartilage developmentbone targetingglycobiologyreceptor mediation

More Related Videos

Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

24.1K
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.6K

Related Experiment Videos

Last Updated: Jun 17, 2025

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
11:20

Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry

Published on: March 29, 2018

7.6K
Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

24.1K
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.6K

Area of Science:

  • Biomedical Engineering
  • Skeletal Biology
  • Drug Delivery Systems

Background:

  • Bone development involves complex pathways, and dysregulation leads to skeletal disorders.
  • The avascular nature of bone and cartilage complicates drug delivery compared to soft tissues.
  • Existing treatments like enzyme infusions, hormone therapy, gene, and cell therapies offer partial improvement but have limitations.

Purpose of the Study:

  • To comprehensively review current bone-targeting strategies for drug delivery.
  • To highlight challenges and limitations in existing bone therapeutic approaches.
  • To emphasize future directions for enhanced bone-targeting systems.

Main Methods:

  • Review of current literature on bone-targeting strategies.
  • Analysis of bone structure and remodeling concepts.
  • Exploration of novel delivery methods and receptor-regulated pathways.

Main Results:

  • Current bone-targeting approaches show promise but do not fully correct skeletal dysfunction, especially growth plate issues.
  • Novel delivery methods require improvements in target specificity, reduced immunogenicity, and prolonged circulation.
  • Targeted drug delivery using organic and inorganic compounds is a promising preclinical approach.

Conclusions:

  • Significant advancements in bone-targeting drug delivery are necessary for effective skeletal treatment.
  • Future strategies should focus on enhancing specificity, minimizing immune responses, and improving drug persistence.
  • Targeted delivery systems hold potential for clinical translation in treating bone disorders.